Brewton’s D.W. McMillan Hospital is not on a list of Alabama health care facilities that received products involved in a recall from the New England Compounding Center, which was tied to an outbreak of fungal meningitis.

The Alabama Department of Public Health on Thursday released a list of health care facilities in Alabama that received products included in the third recall from the New England Compounding Center. These products have no known association with confirmed disease nor have they been proven to be contaminated. Public health officials have notified each facility in order to ensure that NECC products have been removed from their inventory and to discuss the process for contacting their patients. Atmore Community Hospital and Andalusia Regional Medical Center were included on the list.

Out of an abundance of caution, the Food and Drug Administration, Centers for Disease Control and Prevention and ADPH have asked health care facilities to notify all individuals for whom they administered an injectable NECC product, including an ophthalmic drug that is injectable or used in conjunction with eye surgery, or a cardioplegic solution after May 21, 2012. The types of procedures include, but are not limited to, epidurals, joint injections, eye surgeries, and heart surgeries.  

“Alabama health care facilities have had very limited exposure to NECC products, but individuals who have had certain medical procedures using these specific products are being notified,” Dr. Donald Williamson, state health officer, said. “If you have had adverse reactions, contact your health care provider.”

Nineteen Alabama residents have received NECC contaminated steroid products from procedures in Tennessee and Florida. If any patients are identified with symptoms suggestive of meningitis or other infections, they should be referred to the appropriate medical provider.